{"name":"Salarius Pharmaceuticals","slug":"salarius","ticker":"SLRX","exchange":"NASDAQ","domain":"salariuspharma.com","description":"Salarius Pharmaceuticals is a clinical-stage oncology biotechnology company focused on developing innovative treatments for cancer. The company's lead product, Seclidemstat, is being investigated for the treatment of various types of cancer, including Ewing's Sarcoma and other solid tumors. Salarius has a strong pipeline of preclinical and clinical-stage programs, and is working to bring new therapies to patients with limited treatment options. With a focus on precision medicine and targeted therapies, Salarius is well-positioned to make a meaningful impact in the oncology space.","hq":"Houston, TX","founded":0,"employees":"","ceo":"David Arthur","sector":"Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":770027,"netIncome":-5575777,"cash":3022974,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Salarius Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical programs and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"trial","headline":"Salarius Pharmaceuticals Announces Positive Interim Results from Phase 1/2 Clinical Trial of Seclidemstat in Ewing's Sarcoma","summary":"Salarius Pharmaceuticals announced positive interim results from its Phase 1/2 clinical trial of Seclidemstat in patients with Ewing's Sarcoma, demonstrating encouraging efficacy and safety.","drugName":"Seclidemstat","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE94b0lSa2d5TGhfUVZsMkJ4NC1qRHJvdE9hcVZLWlFLNUNfVm03eE9ncDk2aXh6QkE3dVA1MS0yY1dxZVlNVmlfeXh3MENBeGR1R19wTFNiaTFqbERRREFDRWJfck5EZWh1VFhhWTR3?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan","headline":"If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX)","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPU1BncVlKSU96T3lsUXFoVGFQd0J1SDNhMjgyQnVlYkhtUVU4dThDMlU5Y0dtT0pXTVVwT2dybHlETFVHRGRKdjUzdi1qNTNVRmNpOWhmNThVcmg0X2E5aEg4ZlloV3VSNGg0Vy1tNlpFaG5LNFEybnFsT0dOZlc1WlUwdTNLUWZaQUNsX1ZZRE9pc1g2V2RiYXlUY2Y3LU4xdWN5TG9jbVZjenBrdHIyWThfNElyZw?oc=5","date":"2025-11-19","type":"deal","source":"Stock Titan","summary":"Salarius Pharma (NASDAQ: SLRX) notes CapIQ errors, has ~$14M cash post Decoy merger - Stock Titan","headline":"Salarius Pharma (NASDAQ: SLRX) notes CapIQ errors, has ~$14M cash post Decoy merger","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdGxpUTExMG9vSEEyMFNmdFBBY20wSERLSFdfTnBVdXhDNVBKbmw3S0RrWWFsT0d3VG5hLTZhRmJYa1M4SHh3dHNPUFVCSFJ2XzlLQ1lGN0Jmeld1UmJ1THFyZS03SjNUQ1FJNVktenVNYVkzbkRVeXJrZjkwc0Z1YlVRUG0zV2E5Wi1XamkyRG54TUFMemMxRDRhWGVQQ2kyRWJKN1hBUFoxeUVma1AxUnVWTFpJU3M5MmVCM0Mwa3k3Q1hHdHMtSEJKVFEtRTBq?oc=5","date":"2025-11-13","type":"deal","source":"GlobeNewswire","summary":"Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewswire","headline":"Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQWjhvYWdLRWl6ZW1rUnBTSjRtQmV1cHhSTDJWeEhoTDJCdVp4VWpYLXFNc2thM2N0bW9RLUUxSkh4a202N2hHSThOTll5NE9vUU1qdmc3Z1Jnck5MNWVBcmdEaWFVQUJRalQ3U0hnTUZrdTFPQjM5YXhQc2NhNmpBQjdjLWRfOWlN?oc=5","date":"2025-11-12","type":"deal","source":"StocksToTrade","summary":"Salarius Pharmaceuticals Explorates Merger and Funding Moves - StocksToTrade","headline":"Salarius Pharmaceuticals Explorates Merger and Funding Moves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxORWcxanVfbWQ0bGFHX0RvaXU1cGcwQTdVSUhuenZ5OERtdFZFTmpJWkpYMU1XYjdxUWhaM3ZXRVlhYVFUQU9DMXdndkxKb3pUd2d6S3A2ckdxSmJjVUt0MlZQbnRYRTRNQlVCUWdaczVRRkU3S3o5VGJ6UGJwd3ZFRGpSU2MzblA1eWg1Nk1ZNEllSktM?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - Yahoo Finance","headline":"Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQXZxRXlPOHdZT3dVWkhhZDhsYkI3aW11Ym5LREE5UklXSDBULVpqdlNXa0Q4SWR0UFRMbExPV3RoOVlaOGdzSVdTYlBZYUQ4YnpNX1h0alNSZkFYaUFJc0hidXVOM3pvM0FTTlBGaE9lUV9Rcmp0QnBsenlnTWU5NVJnbkJ1NTVYWE1CbHdPZnl3VHpDeFQ0OFVMOVR0MUtvQUlkalJJR054Qm14VWVkTGN3R3NmYlBGYUJ0QXlKclU?oc=5","date":"2025-08-26","type":"pipeline","source":"Eurasia Business News","summary":"Stocks to Watch Today : AMD, Eli Lilly, EchoStar, Trump Media, NovaBay Pharma, MongoDB - Eurasia Business News","headline":"Stocks to Watch Today : AMD, Eli Lilly, EchoStar, Trump Media, NovaBay Pharma, MongoDB","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Clovis Oncology","Agenus","Nektar Therapeutics"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":0,"period":"2022-12-31"},{"value":1840216,"period":"2021-12-31"},{"value":1840216,"period":"2021-12-31"},{"value":5233301,"period":"2020-12-31"},{"value":5233301,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":770027,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5575777,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":3022974,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}